Table 1.
Baseline characteristics.
| Characteristic | Cabozantinib (N = 79) | Sunitinib (N = 78) |
|---|---|---|
| Age (years) | 63 (56—69) | 64 (57—71) |
| Sex | ||
| Male | 66 (84%) | 57 (73%) |
| Female | 13 (16%) | 21 (27%) |
| Ethnic origin | ||
| White | 70 (89%) | 75 (96%) |
| Black or African American | 3 (4%) | 2 (3%) |
| Other | 7 (9%) | 1 (1%) |
| ECOG performance status | ||
| 0 | 36 (46%) | 36 (46%) |
| 1 | 33 (42%) | 32 (41%) |
| 2 | 10 (13%) | 10 (13%) |
| IMDC risk group | ||
| Intermediate | 64 (81%) | 63 (81%) |
| Poor | 15 (19%) | 15 (19%) |
| Bone metastasis per IxRS | ||
| Yes | 29 (37%) | 28 (36%) |
| No | 50 (63%) | 50 (64%) |
| Prior nephrectomy | ||
| Yes | 57 (72%) | 60 (77%) |
| No | 22 (28%) | 18 (23%) |
| MET statusa | ||
| Positive | 32 (41%) | 30 (38%) |
| Negative | 39 (49%) | 30 (38%) |
| Missing | 8 (10%) | 18 (23%) |
| Sum of diameters of lesions per RECIST per investigator (cm) | 7.2 (4.3—11.7) | 8.1 (4.7—13.4) |
| Number of metastatic sites per investigator | ||
| 1 | 17 (22%) | 26 (33%) |
| 2 | 37 (47%) | 20 (26%) |
| ≥3 | 25 (32%) | 32 (41%) |
| Metastatic sites per investigator | ||
| Nodal | 45 (57%) | 42 (54%) |
| Lung | 55 (70%) | 54 (69%) |
| Liver | 15 (19%) | 20 (26%) |
| Bone | 31 (39%) | 30 (38%) |
| CNS/brain | 3 (4%) | 2 (3%) |
Data are n (%) or median (IQR).
Abbreviations: IMDC, International Metastatic Renal Cell Carcinoma Database Consortium criteria; IxRS, interactive web/voice response system.
a
Based on tumour MET levels by immunohistochemistry.